OpenAI is making a major push into biodefense, backing startups, convening government officials, and developing AI tools to detect biological threats before they become crises.
Investments and Startups
OpenAI led a $15 million seed round for Red Queen Bio on November 13, 2025. The startup focuses on mitigating biological risks as AI capabilities become more accessible. Weeks earlier, Valthos emerged from stealth with $30 million to build an early warning system for pathogens and bioweapons.
Summits and Frameworks
OpenAI hosted a biodefense summit in July 2025, bringing together government entities, NGOs, and researchers. The company also maintains a Preparedness Framework that evaluates biological capabilities of its models and enforces safeguards at high-risk thresholds.
GPT-Rosalind
OpenAI is developing GPT-Rosalind, a biology-focused model that could advance AI in life sciences. Named after Rosalind Franklin, the chemist whose work was critical to understanding DNA's structure, the model signals OpenAI's commitment to specialized biological AI.
Investor Implications
The $45 million deployed across Red Queen Bio and Valthos establishes a baseline for OpenAI's focus on biosecurity. Key risks include execution-where false positives waste resources and false negatives cost lives-and regulatory constraints as governments address AI's dual-use potential.